Bennett Myers, MD
Neurology · Amherst, NYNPI 1437211414
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $279,458 of the $431,698 with a category attached, or 64.7%. 60 manufacturers reported payments, led by Genentech USA, Inc. at 25.5% of the total. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,974 payments — averaging $218.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$110K
- Argenx US, Inc.$83K
- Biogen$75K
- AbbVie$40K
- AstraZeneca$28K
- Amgen$22K
- plus $72K from 54 others
Across 288 payments — averaging $10,522 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.7M
- Novartis$115K
- Sanofi$81K
- Roche Products Limited$56K
- AbbVie$18K
- Jazz Pharmaceuticals Inc.$16K
- plus $44K from 5 others
Across 7 payments — averaging $44,462 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$311K
What the payments were for
- Consulting fees$78,40118%
- Speaking & faculty fees$279,45865%
- Travel & lodging$35,7948%
- Food & beverage$37,6119%
- Education$4350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$431,698 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 101 | $1,416,264 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 83 | $613,155 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 15 | $190,100 |
| IngrezzaValbenazine Tosylate | 14 | $101,471 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $100,109 |
| Dalfampridine ErDalfampridine | 17 | $20,437 |
| Riluzole | 82 | $5,240 |
| Gabapentin | 145 | $2,673 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 60 | $2,572 |
| Pregabalin | 71 | $2,528 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 58 | $2,420 |
| Rasagiline Mesylate | 18 | $1,708 |
| Pyridostigmine Bromide | 32 | $1,153 |
| Baclofen | 37 | $833 |
| Tizanidine Hcl | 40 | $790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $132 | $613,15583 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $814 | $101,47114 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $145 | $1,15332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in Amherst
- Nicolas SaikaliAmherst$1.5M
- Jennifer McVigeAmherst$982K
- Laszlo MechtlerAmherst$347K
- Wisam ElmalikAmherst$289K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.